LETTER TO FRONTIERS OF MEDICINE |
|
|
|
Expression status of GATA3 and mismatch repair proteins in upper tract urothelial carcinoma |
Yue Wang1, Jinxia Zhang1, Yunfan Wang1, Shufang Wang1, Yu Zhang1, Qi Miao1, Fei Gao2, Huiying He2() |
1. Department of Pathology, Peking University Shougang Hospital, Beijing 100144, China 2. Department of Pathology, School of Basic Medical Sciences, Peking University Third Hospital, Peking University Health Science Center, Beijing 100083, China |
|
|
Abstract GATA binding protein 3 (GATA3) and mismatch repair (MMR) deficiency contribute to the development of urothelial carcinoma. However, the combined expression of GATA3 and microsatellite instability (MSI) in upper tract urothelial carcinoma (UTUC) and its prognostic value have not been investigated. Here, we immunohistochemically stained GATA3 and MMR proteins in 108 UTUC samples. GATA3 was positive in 74 cases, and its expression was significantly lower than in adjacent benign urothelium (P<0.001). Loss of GATA3 expression was statistically associated with adverse clinicopathologic parameters, such as advanced stage, lymphovascular invasion, neural invasion, lymph node metastasis, and extensive necrosis. Cancer-specific survival (CSS, P=0.028) and disease-free survival (DFS, P=0.024) were significantly shorter in patients with GATA3 negative tumors than in patients with GATA3 positive tumors. The absence of MMR proteins was observed in 8.3% of the cases, and focal staining was identified in 13.0%. When using “lax criteria” which resulted in counting cases as negative where MMR staining was in fact focally positive (<5%), we found that GATA3 was inversely associated with MSI (P=0.005). Moreover, GATA3−/microsatellite stability (MS) tumors were correlated with advanced pT stage (P<0.001) and poor outcome (P=0.019 for CSS, P=0.016 for DFS) compared with GATA3+/MSI ones. The GATA3−/MSI cases had unfavorable clinical outcomes compared with GATA3+/MSI cases (P=0.008 for CSS, P=0.023 for DFS). This finding raises a question as to whether GATA3 interacts with MSI through the TGF-β signaling pathway and regulates UTUC progression.
|
Keywords
upper tract urothelial carcinoma
GATA binding protein 3
mismatch repair
microsatellite instability
prognosis
|
Corresponding Author(s):
Huiying He
|
Just Accepted Date: 11 March 2019
Online First Date: 22 April 2019
Issue Date: 16 December 2019
|
|
1 |
RL Siegel, KD Miller, A Jemal. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67(1): 7–30
https://doi.org/10.3322/caac.21387
pmid: 28055103
|
2 |
XP Chen, GY Xiong, XS Li, SF Matin, M Garcia, D Fang, TY Wang, W Yu, K Gong, Y Song, ZS He, Q He, LQ Zhou. Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China. BJU Int 2013; 112(7): 917–924
https://doi.org/10.1111/bju.12238
pmid: 23905945
|
3 |
N Singla, D Fang, X Su, Z Bao, Z Cao, SM Jafri, G Xiong, L Zhang, R Hutchinson, A Sagalowsky, Y Lotan, X Li, L Zhou, JD Raman, V Margulis. A multi-institutional comparison of clinicopathologic characteristics and oncologic outcomes of upper tract urothelial carcinoma in China and the United States. J Urol 2017; 197(5): 1208–1213
https://doi.org/10.1016/j.juro.2016.11.094
pmid: 27887951
|
4 |
G Xiong, J Liu, Q Tang, Y Fan, D Fang, K Yang, F Xie, M Zhang, L Zhang, L Liu, C Zhang, L Yao, L Yang, W Ci, W Zhao, Y Gong, Q He, K Gong, Z He, G Wang, X Li, Y Guo, L Zhou. Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma. Epigenomics 2015; 7(5): 733–744
https://doi.org/10.2217/epi.15.34
pmid: 25912368
|
5 |
IC Ho, P Vorhees, N Marin, BK Oakley, SF Tsai, SH Orkin, JM Leiden. Human GATA-3: a lineage-restricted transcription factor that regulates the expression of the T cell receptor alpha gene. EMBO J 1991; 10(5): 1187–1192
https://doi.org/10.1002/j.1460-2075.1991.tb08059.x
pmid: 1827068
|
6 |
ML Asselin-Labat, KD Sutherland, H Barker, R Thomas, M Shackleton, NC Forrest, L Hartley, L Robb, FG Grosveld, J van der Wees, GJ Lindeman, JE Visvader. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007; 9(2): 201–209
https://doi.org/10.1038/ncb1530
pmid: 17187062
|
7 |
RS Gonzalez, J Wang, T Kraus, H Sullivan, AL Adams, C Cohen. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. Hum Pathol 2013; 44(6): 1065–1070
https://doi.org/10.1016/j.humpath.2012.09.010
pmid: 23266442
|
8 |
JP Higgins, G Kaygusuz, L Wang, K Montgomery, V Mason, SX Zhu, RJ Marinelli, JC Presti Jr, M van de Rijn, JD Brooks. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 2007; 31(5): 673–680
https://doi.org/10.1097/01.pas.0000213438.01278.5f
pmid: 17460449
|
9 |
Y Li, H Ishiguro, T Kawahara, E Kashiwagi, K Izumi, H Miyamoto. Loss of GATA3 in bladder cancer promotes cell migration and invasion. Cancer Biol Ther 2014; 15(4): 428–435
https://doi.org/10.4161/cbt.27631
pmid: 24448324
|
10 |
J Sun, H He, S Pillai, Y Xiong, S Challa, L Xu, S Chellappan, S Yang. GATA3 transcription factor abrogates Smad4 transcription factor-mediated fascin overexpression, invadopodium formation, and breast cancer cell invasion. J Biol Chem 2013; 288(52): 36971–36982
https://doi.org/10.1074/jbc.M113.506535
pmid: 24235142
|
11 |
NF de Miranda, M van Dinther, BE van den Akker, T van Wezel, P ten Dijke, H Morreau. Transforming growth factor b signaling in colorectal cancer cells with microsatellite instability despite biallelic mutations in TGFBR2. Gastroenterology 2015; 148(7): 1427–37.e8
https://doi.org/10.1053/j.gastro.2015.02.052
pmid: 25736321
|
12 |
N Amira, J Rivet, H Soliman, G Cancel-Tassin, A Le Duc, A Janin, O Cussenot. Microsatellite instability in urothelial carcinoma of the upper urinary tract. J Urol 2003; 170(4 Pt 1): 1151–1154
https://doi.org/10.1097/01.ju.0000086551.22844.cd
pmid: 14501713
|
13 |
SC Skeldon, K Semotiuk, M Aronson, S Holter, S Gallinger, A Pollett, C Kuk, B van Rhijn, P Bostrom, Z Cohen, NE Fleshner, MA Jewett, S Hanna, SF Shariat, TH Van Der Kwast, A Evans, J Catto, B Bapat, AR Zlotta. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol 2013; 63(2): 379–385
https://doi.org/10.1016/j.eururo.2012.07.047
pmid: 22883484
|
14 |
E Mylona, A Zarogiannos, A Nomikos, I Giannopoulou, I Nikolaou, A Zervas, L Nakopoulou. Prognostic value of microsatellite instability determined by immunohistochemical staining of hMSH2 and hMSH6 in urothelial carcinoma of the bladder. APMIS 2008; 116(1): 59–65
https://doi.org/10.1111/j.1600-0463.2008.00760.x
pmid: 18254781
|
15 |
MA Rubin, R Dunn, M Strawderman, KJ Pienta. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002; 26(3): 312–319
https://doi.org/10.1097/00000478-200203000-00004
pmid: 11859202
|
16 |
S Inoue, T Mizushima, K Fujita, A Meliti, H Ide, S Yamaguchi, H Fushimi, GJ Netto, N Nonomura, H Miyamoto. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator. Hum Pathol 2017; 64: 83–90
https://doi.org/10.1016/j.humpath.2017.04.003
pmid: 28428106
|
17 |
E Mangold, C Pagenstecher, W Friedl, HP Fischer, S Merkelbach-Bruse, M Ohlendorf, N Friedrichs, S Aretz, R Buettner, P Propping, M Mathiak. Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol 2005; 207(4): 385–395
https://doi.org/10.1002/path.1858
pmid: 16216036
|
18 |
P Joost, N Veurink, S Holck, L Klarskov, A Bojesen, M Harbo, B Baldetorp, E Rambech, M Nilbert. Heterogenous mismatch-repair status in colorectal cancer. Diagn Pathol 2014; 9(1): 126–135
https://doi.org/10.1186/1746-1596-9-126
pmid: 24968821
|
19 |
C Seitz, A Gupta, SF Shariat, K Matsumoto, W Kassouf, TJ Walton, HM Fritsche, W Otto, S Tritschler, PJ Bastian, J Carballido, V Ficarra, PI Karakiewicz, W Artibani, G Mazzoleni, G Novara. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. J Urol 2010; 184(5): 1895–1900
https://doi.org/10.1016/j.juro.2010.06.106
pmid: 20846680
|
20 |
GP Paner, C Annaiah, C Gulmann, P Rao, JY Ro, DE Hansel, SS Shen, A Lopez-Beltran, M Aron, DJ Luthringer, M De Peralta-Venturina, Y Cho, MB Amin. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Hum Pathol 2014; 45(7): 1473–1482
https://doi.org/10.1016/j.humpath.2014.02.024
pmid: 24780825
|
21 |
S Bai, AL Nunez, S Wei, A Ziober, Y Yao, JE Tomaszewski, Z Bing. Microsatellite instability and TARBP2 mutation study in upper urinary tract urothelial carcinoma. Am J Clin Pathol 2013; 139(6): 765–770
https://doi.org/10.1309/AJCPBSLP8XHSWLOW
pmid: 23690119
|
22 |
K Inamura. Bladder cancer: new insights into its molecular pathology. Cancers (Basel) 2018; 10(4): 100
https://doi.org/10.3390/cancers10040100
pmid: 29614760
|
23 |
JI Warrick, V Walter, H Yamashita, E Chung, L Shuman, VO Amponsa, Z Zheng, W Chan, TL Whitcomb, F Yue, T Iyyanki, YI Kawasawa, M Kaag, W Guo, JD Raman, JS Park, DJ DeGraff. FOXA1, GATA3 and PPARγ cooperate to drive luminal subtype in bladder cancer: a molecular analysis of established human cell lines. Sci Rep 2016; 6(1): 38531
https://doi.org/10.1038/srep38531
pmid: 27924948
|
24 |
V Dadhania, M Zhang, L Zhang, J Bondaruk, T Majewski, A Siefker-Radtke, CC Guo, C Dinney, DE Cogdell, S Zhang, S Lee, JG Lee, JN Weinstein, K Baggerly, D McConkey, B Czerniak. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 2016; 12: 105–117
https://doi.org/10.1016/j.ebiom.2016.08.036
pmid: 27612592
|
25 |
IB Bahria-Sediki, N Yousfi, C Paul, M Chebil, M Cherif, R Zermani, AB El Gaaied, A Bettaieb. Clinical significance of T-bet, GATA-3, and Bcl-6 transcription factor expression in bladder carcinoma. J Transl Med 2016; 14(1): 144–154
https://doi.org/10.1186/s12967-016-0891-z
pmid: 27237631
|
26 |
B Shi, B Su, D Fang, Y Tang, G Xiong, Z Guo, Q He, X Yang, W Zhao, Y Guo, X Li, L Zhou. High expression of KPNA2 defines poor prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. BMC Cancer 2015; 15(1): 380–391
https://doi.org/10.1186/s12885-015-1369-8
pmid: 25956057
|
27 |
F Du, P Yuan, T Wang, J Zhao, Z Zhao, Y Luo, B Xu. The significance and therapeutic potential of GATA3 expression and mutation in breast cancer: a systematic review. Med Res Rev 2015; 35(6): 1300–1315
https://doi.org/10.1002/med.21362
pmid: 26313026
|
28 |
A García-Tello, F Ramón de Fata, G Andrés, S Ropero, JI López, JC Angulo. DNA repair genes and prognosis in sporadic forms of urothelial carcinoma of the upper urinary tract. Actas Urol Esp 2014; 38(9): 600–607
https://doi.org/10.1016/j.acuroe.2014.09.005
pmid: 24958312
|
29 |
HL Harper, JK McKenney, B Heald, A Stephenson, SC Campbell, T Plesec, C Magi-Galluzzi. Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome. Mod Pathol 2017; 30(1): 146–156
https://doi.org/10.1038/modpathol.2016.171
pmid: 27713421
|
30 |
Q Li, A Bagrodia, EK Cha, JA Coleman. Prognostic genetic signatures in upper rract urothelial carcinoma. Curr Urol Rep 2016; 17(2): 12–22
https://doi.org/10.1007/s11934-015-0566-y
pmid: 26757906
|
31 |
M Rouprêt, G Fromont, AR Azzouzi, JW Catto, G Vallancien, FC Hamdy, O Cussenot. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology 2005; 65(6): 1233–1237
https://doi.org/10.1016/j.urology.2005.01.019
pmid: 15922421
|
32 |
R Parsons, LL Myeroff, B Liu, JK Willson, SD Markowitz, KW Kinzler, B Vogelstein. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res 1995; 55(23): 5548–5550
pmid: 7585632
|
33 |
J Lee, S Ballikaya, K Schönig, CR Ball, H Glimm, J Kopitz, J Gebert. Transforming growth factor β receptor 2 (TGFBR2) changes sialylation in the microsatellite unstable (MSI) Colorectal cancer cell line HCT116. PLoS One 2013; 8(2): e57074
https://doi.org/10.1371/journal.pone.0057074
pmid: 23468914
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|